Literature DB >> 9226924

Actinomyces graevenitzii sp. nov., isolated from human clinical specimens.

C P Ramos1, E Falsen, N Alvarez, E Akervall, B Sjödén, M D Collins.   

Abstract

Four strains of a previously unknown, catalase-negative, facultatively anaerobic, gram-positive, rod-shaped organism originating from humans were characterized by biochemical, chemical, and molecular taxonomic methods. The four strains phenotypically closely resembled one another, and although they possessed characteristics consistent with membership in the genus Actinomyces, they differed from all previously recognized species of this genus. The results of comparative 16S rRNA gene sequencing studies demonstrated that the unknown human bacterium was phylogenetically a member of the genus Actinomyces. Within the genus Actinomyces, the unidentified bacterium formed a loose, but statistically significant, association with a subgroup which included Actinomyces bovis, the type species of the genus. 16S rRNA sequence divergence values of > 6%, however, unequivocally demonstrated that the unidentified bacterium represents a new subline of the genus Actinomyces. A new species, Actinomyces graevenitzii, is proposed for the four new isolates. The type strain of A. graevenitzii is CCUG 27294.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226924     DOI: 10.1099/00207713-47-3-885

Source DB:  PubMed          Journal:  Int J Syst Bacteriol        ISSN: 0020-7713


  14 in total

1.  Development of amplified 16S ribosomal DNA restriction analysis for identification of Actinomyces species and comparison with pyrolysis-mass spectrometry and conventional biochemical tests.

Authors:  V Hall; G L O'Neill; J T Magee; B I Duerden
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

2.  Identification of clinical isolates of actinomyces species by amplified 16S ribosomal DNA restriction analysis.

Authors:  V Hall; P R Talbot; S L Stubbs; B I Duerden
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

3.  Characterization of some actinomyces-like isolates from human clinical sources: description of Varibaculum cambriensis gen nov, sp nov.

Authors:  Val Hall; Matthew D Collins; Paul A Lawson; Roger A Hutson; Enevold Falsen; Elisabeth Inganas; Brian Duerden
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

4.  Multicenter evaluation of the updated and extended API (RAPID) Coryne database 2.0.

Authors:  G Funke; F N Renaud; J Freney; P Riegel
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

Review 5.  Actinomyces and related organisms in human infections.

Authors:  Eija Könönen; William G Wade
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 6.  Disseminated coinfection with Actinomyces graevenitzii and Mycobacterium tuberculosis: case report and review of the literature.

Authors:  Andreas Tietz; Kenneth E Aldridge; Julio E Figueroa
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

7.  Characterization of Actinomyces isolates from infected root canals of teeth: description of Actinomyces radicidentis sp. nov.

Authors:  M D Collins; L Hoyles; S Kalfas; G Sundquist; T Monsen; N Nikolaitchouk; E Falsen
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

8.  Pseudo-outbreak of Actinomyces graevenitzii associated with bronchoscopy.

Authors:  David R Peaper; Nancy L Havill; Michael Aniskiewicz; Deborah Callan; Olivia Pop; Dana Towle; John M Boyce
Journal:  J Clin Microbiol       Date:  2014-10-29       Impact factor: 5.948

9.  Actinomyces graevenitzii pulmonary abscess mimicking tuberculosis in a healthy young man.

Authors:  Smaranda Gliga; Mathilde Devaux; Marine Gosset Woimant; Dominique Mompoint; Christian Perronne; Benjamin Davido
Journal:  Can Respir J       Date:  2014 November/December       Impact factor: 2.409

10.  Actinomyces cardiffensis sp. nov. from human clinical sources.

Authors:  Val Hall; Mattew D Collins; Roger Hutson; Enevold Falsen; Brian I Duerden
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.